Monograph Details
|
|
Hematology
> Bleeding disorders
|
|
AMICAR INJECTION |
| Manufacturer |
|
Xanodyne Pharmacal, Inc. |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Hemostatic (plasmin and plasminogen activator inhibitor). |
| Generic Name |
|
Aminocaproic acid 250mg/mL; soln for IV infusion after dilution; contains benzyl alcohol. |
| Also |
• AMICAR ORAL SOLUTION
• AMICAR TABLETS
|
| Indications |
|
Bleeding associated with fibrinolysis. |
| Children |
|
Not recommended. |
| Adults |
|
4–5g (in 250mL of diluent) by IV infusion during the 1st hour, then 1g/hour (in 50mL of diluent) for 8 hours or until bleeding is controlled. |
| Contraindications |
|
Active intravascular clotting process. Disseminated intravascular coagulation without concomitant heparin. |
| Precautions |
|
Upper urinary tract bleeding: not recommended. Cardiac, hepatic or renal disease. Risk of myopathy with long-term use; monitor creatine phosphokinase (CPK); discontinue if CPK rises. Avoid rapid IV administration. Neonates. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Avoid concomitant Factor IX complex or Anti-inhibitor Coagulant concentrates; may increase thrombosis risk. |
| Adverse Reactions |
|
Inj site reactions, bradycardia, hypotension, GI upset, edema, headache, malaise, CNS effects, thrombosis, others; rare: myopathy. |
| How Supplied |
Tabs—100
Oral soln—473mL
Vials (20mL)—1 |
| Additional Resources |
|
• Related Prescribing Note |
|
|
|
|
